5CV.DEライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (29 4月 2024 @ 21:18):

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA)...

Stats
本日の出来高	51 304.00
平均出来高	78 272.00
時価総額	485.38M
EPS	€-0.217 ( 2023-09-30 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-1.470
ATR14	€0.0100 (0.46%)

ボリューム相関

長: -0.08 (neutral)

短: -0.34 (neutral)

Signal:(45.951) Neutral

CureVac N.V. 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

CureVac N.V. 相関 - 通貨/商品

-0.25
( neutral )

-0.24
( neutral )

0.00
( neutral )

-0.06
( neutral )

0.57
( weak )

0.28
( neutral )

CureVac N.V. 財務諸表

Annual	2023
収益:	€52.66M
総利益:	€-91.08M (-172.97 %)
EPS:	€-1.150

FY	2023
収益:	€52.66M
総利益:	€-91.08M (-172.97 %)
EPS:	€-1.150

FY	2022
収益:	€67.42M
総利益:	€-116.57M (-172.91 %)
EPS:	€-1.320

FY	2021
収益:	€102.99M
総利益:	€-135.21M (-131.28 %)
EPS:	€-2.34

Financial Reports:

No articles found.

CureVac N.V.

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.